Table 1 IGF-1R targeted drugs evaluated in human trials
From: IGF-1R targeting in cancer – does sub-cellular localization matter?
DRUG | CLASS |
|---|---|
AMG479 (Ganitumab) | Human monoclonal antibody targeting IGF-1R |
AVE1642 | Human monoclonal antibody targeting IGF-1R |
BIIB022 | Human monoclonal antibody targeting IGF-1R |
CP-751,871 (figitumab) | Human monoclonal antibody targeting IGF-1R |
IMCA12 (cixutumumab) | Human monoclonal antibody targeting IGF-1R |
MK7454 (robatumumab) | Human monoclonal antibody targeting IGF-1R |
MK0646 (dalotuzumab) | Human monoclonal antibody targeting IGF-1R |
MM141 (istiratumab) | Human monoclonal bispecific antibody targeting IGF-1R and ErbB3 |
RG1507 (teprotumumab) | Human monoclonal antibody targeting IGF-1R |
AXL1717 (picropodophyllotoxin) | Small molecule non ATP-competitive IGF-1R kinase inhibitor |
BMS-754,807 | Small molecule ATP-competitive IGF-1R kinase inhibitor |
KW-2450 | Small molecule IGF-1R and InsR kinase inhibitor |
OSI906 (Linsitinib) | Small molecule ATP-competitive IGF-1R and InsR kinase inhibitor |
PL225B | Small molecule IGF-1R kinase inhibitor |
XL228 | Multi-targeted small molecule inhibitor of the IGF1R, Src, Abl tyrosine kinases |
IGV-001 | Biologic-device; patient derived GBM cells treated with an antisense oligodeoxynucleotide towards IGF-1R |